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ABSTRACT 
 
In this study, fluid bed granulation was applied to improve the dissolution of nimodipine and spironolactone, two 
very poorly water-soluble drugs. Granules were obtained with different amounts of sodium dodecyl sulfate and 
croscarmellose sodium and then compressed into tablets. The dissolution behavior of the tablets was studied by 
comparing their dissolution profiles and dissolution efficiency with those obtained from physical mixtures of the 
drug and excipients subjected to similar conditions. Statistical analysis of the results demonstrated that the fluid bed 
granulation process improves the dissolution efficiency of both nimodipine and spironolactone tablets. The addition 
of either the surfactant or the disintegrant employed in the study proved to have a lower impact on this improvement 
in dissolution than the fluid bed granulation process. 
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INTRODUCTION 
 
Over the last decade, there has been an increase in 
drugs with high lipophilicity and poor water-
solubility. These physicochemical characteristics 
lead to problematic biopharmaceutical properties, 
such as slow or incomplete absorption, which may 
impair bioavailability. A drug must dissolve in 
physiological intestinal fluids and be adequately 
absorbed in order to result in successful clinical 
treatment (Murali Mohan Babu et al. 2002; 
Stegeman et al. 2007). Several attempts have been 
made to enhance dissolution profiles and, 
therefore, the absorption and bioavailability of 
water-insoluble drugs. The use of water-soluble 
salts and polymorphic forms, as well as the 
formation of water-soluble molecular complexes, 
drug micronization, solid dispersions, co-
precipitation, microencapsulation, spray-drying 
and co-grinding of drugs with commonly used 
excipients are some of the formulation tools that 
have been observed to enhance the dissolution 
characteristics of water-insoluble drugs (Leuner 
and Dressman 2000; Vogt et al. 2008a; Vogt et al. 
2008b; Fahmy and Kassem 2008). 
The granulation process is a pharmaceutical 
operation that obtains large granules from fine 
powders with the aim of improving flowability, 
appearance, mixing properties and the physical 
and chemical properties of these powders. In tablet 
manufacturing, a continuous production line, 
including several operations like granulation, 
drying and coating, can be executed in fluid bed 
equipment (Tardos et al. 1997; Iveson et al. 2001; 
Vervaet and Remon 2005).  
The fluid bed granulation process consists of 
spraying a binder solution, dispersion or 
suspension onto a physical mixture, where 
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particles are suspended by air flow. These particles 
are wet by the binder solution, and liquid bridges 
are formed when they collide, leading to the 
acquisition of granules. Certain conditions, such as 
the spray rate and concentration of the binder 
solution, primary particle size, manufacturing 
processes, fluidizing air velocity and formulation 
can affect the granule microstructure and bed 
moisture level, leading to a lower rate of granule 
breakage (Bouffard et al. 2005; Ansari and 
Stepanek 2008). 
However, despite the recognized utility of the fluid 
bed for improving the dissolution of poorly water-
soluble drugs, there are no studies in which the 
drugs nimodipine and spironolactone have been 
processed using this technology for the production 
of granules and subsequent compression. It is 
important to emphasize that nimodipine and 
spironolactone are classified as class II and class II 
or IV, respectively, according to the 
Biopharmaceutics Classification System 
(Lindenberg et al. 2004; Papageorgiou et al. 2006). 
The purpose of this study was to investigate the 
feasibility of using the fluid bed technique to 
produce granules of these poorly water-soluble 
drugs, with improved dissolution rates. Dissolution 
efficiencies of the tablets produced from the fluid 
bed granules were compared to those obtained 
from the physical mixtures of the ingredients. 
Moreover, the role of sodium dodecyl sulfate and 
croscarmellose sodium in enhancing drug 
dissolution was evaluated. 
 
 
MATERIAL AND METHODS 
 
Material 
Nimodipine and spironolactone were obtained 
from Labogen S/A Química Fina e Biotecnologia 
(Indaiatuba, Brazil) and Gerbrás Química 
Farmacêutica (Diadema, Brazil), respectively. 
Copovidone (Kollidon® VA64) was kindly 
donated by BASF S.A. (São Paulo, Brazil), and 
the other excipients, lactose M 200, talc, colloidal 
silicon dioxide, microcrystalline cellulose type 
101, magnesium stearate, sodium dodecyl sulfate 
and croscarmellose sodium were all of 
pharmaceutical grade. The reagents sodium 
acetate, hydrochloric acid and glacial acetic acid 
were all of analytical grade. 
 
Preparation of nimodipine and spironolactone 
tablets 
Nimodipine and spironolactone granules 
containing 10.0% of the drug, 1.0% Kollidon® 
VA64, 1.0% talc, 1.0% colloidal silicon dioxide 
and different amounts of sodium dodecyl sulphate 
(0 to 2.0%) and croscarmellose sodium (0 to 1.0%) 
were prepared. The formulations were completed 
to 100% with a 1:1 lactose-microcrystalline 
cellulose mixture. Granule compositions are 
shown in the Table 1. The binder dispersion was 
prepared by mixing the drug, Kollidon® VA64 and 
sodium dodecyl sulfate. The mixture was 
completed to 50.0 mL with distilled water, and this 
was placed in an Ultra Turrax T 25 Digital 
Homogenizer (Ika Labortechnik, Staufen, 
Germany) for one minute, in order to disperse the 
material. 
Initially, lactose, microcrystalline cellulose, talc 
and colloidal silicon dioxide were homogenized in 
a Mycrolab® fluid bed system (Hüttlin, Steinen, 
Germany), for five minutes, under the following 
conditions: air volume: of 7.0 m3 h-1; inlet 
temperature: 50.0ºC; bottom spray pressure: 0.8 
bar; microclimate: 0.4 bar; and filter clean 
pressure: 2.4 bar. The binder dispersion was added 
to the homogenized powders by means of a 
peristaltic pump (Watson-Marlow Bredel Pumps, 
England), at a rate of 10 rpm. The pump was 
connected to a 0.8 mm bottom spray nozzle for 
nimodipine, and a 0.6 mm nozzle for 
spironolactone. After applying the binder solution, 
the granules were dried in the fluid bed under the 
same conditions for five minutes. When 
applicable, croscarmellose sodium was added and 
mixed to the dried formulations. Finally, 
magnesium stearate was manually added to all 
formulations and they were stirred for two 
minutes. The physical mixtures were accurately 
prepared by weighing and mixing the same 
ingredients used in the preparation of granules. 
The final drug content in the granules was 
determined by means of a previously-validated 
UV spectrophotometric method, in order to define 
the tablet weight. 
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Table 1 - Composition of the granules, physical mixtures and the tablets obtained from these materials. 
Formulation (Granules 
or Physical mixtures) 
Sodium dodecyl 
sulfate (%) 
Croscarmellose sodium* 
(%) 
Lactose-microcrystalline 
cellulose mixture (1:1) (%) 
1 0 0 89.0 
2 0.5 0 88.5 
3 1.0 0 88.0 
4 2.0 0 87.0 
5 0 1.0 88.0 
6 0.5 1.0 87.5 
7 1.0 1.0 87.0 
8 2.0 1.0 86.0 
*Manually added after granulation process.  
 
 
After being accurately weighed, the granules and 
the physical mixtures were compressed into tablets 
using a hydraulic press (Fred S. Carver inc., New 
Jersey, USA). A compression force of 0.5 ton was 
applied for one minute. 
 
Dissolution tests 
Dissolution tests were performed in a D-800 
Logan Dissolution Tester (Logan Instruments 
Corp., New Jersey, USA) multi-bath dissolution 
test system. An assay of each tablet obtained from 
physical mixture (PM) and granules (G) was 
executed in triplicate (n = 3). The nimodipine test 
was carried out according to the British 
Pharmacopoeia method (British Pharmacopoeia 
2010), using apparatus 2 at 75 rpm with 900 mL of 
acetate buffer, pH 4.5, and 0.3% of sodium 
dodecyl sulfate. In order to prevent tablet floating, 
the dissolution test for spironolactone was 
conducted with apparatus 1 at 100 rpm and a 
different pharmacopoeia method (United States 
Pharmacopeia 2009), in 0.1 M hydrochloric acid 
and 0.1% of sodium dodecyl sulfate.  
The medium, which was previously deaerated in 
an ultrasonic bath at 50ºC and filtered through a 
0.45 µm membrane, was kept at 37 ± 0.5ºC. The 
glass dissolution vessels were covered to minimize 
evaporation. Manual sampling aliquots of 10.0 mL 
were extracted at 2, 5, 10, 15, 20, 30, 45 and 60 
minutes for nimodipine, and at 3, 5, 10, 15, 20, 30, 
45, 60 and 90 minutes for spironolactone. 
A Beckman Coulter DU® 640 UV–VIS 
Spectrophotometer (California, USA), with 1.0 cm 
quartz cells, adjusted to 360 nm for nimodipine 
and 238 nm for spironolactone, was used to record 
the samples. Other experiments, such as linearity, 
precision, recovery and absence of interference, 
were also conducted in order to achieve analytical 
validation (data not shown).  
The dissolution profiles were compared through a 
model-independent method: dissolution efficiency 
(DE). The DE was calculated from the area under 
the dissolution curve versus time, calculated by 
means of the trapezoidal rule and expressed as a 
percentage of the rectangular area described by 
100% dissolution in the same time. The results of 
DE were compared by means of ANOVA 
(analysis of variance) and were evaluated by 
interaction plot, using Minitab® 15 statistical 
software to analyze the relationship between the 
DE values of the physical mixture and granules, 
and the concentration of sodium dodecyl sulfate, 
as well as the presence or absence of 
croscarmellose sodium. 
 
 
RESULTS AND DISCUSSION 
 
The dissolution profiles obtained from the tablets 
obtained from granules (G) and from physical 
mixtures (PM) are presented for nimodipine in 
Figure 1, and for spironolactone in Figure 2.  
According to Figure 1A, nimodipine tablets 
obtained from physical mixtures (PM1, PM2, PM3 
and PM4) did not present adequate dissolution 
profiles for immediate-release tablets. Drug 
release from formulations PM1, PM2 and PM3 
was less than 40.0% within 60 minutes, while 
formulation PM4 released more than 80.0% of the 
drug over the same timeframe, probably as a result 
of the addition of 2.0% sodium dodecyl sulfate, 
which increased powder wettability (Vogt et al. 
2008b). 
The addition of a disintegrant to some 
formulations (PM5, PM6, PM7 and PM8), Figure 
1B, led to an increase in the percentage of 
nimodipine dissolved, more than 85.0% within 60 
minutes. But the dissolution profiles show that 
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drug release from tablets obtained from physical 
mixtures containing the disintegrant are no faster 
than from tablets obtained from granules obtained 
by spraying the dispersed drug in the fluid bed 
equipment (Fig. 1B and Fig. 1D).  
 
 
 
Figure 1 - Nimodipine dissolution profiles in acetate buffer solution, pH 4.5, with 0.3% sodium 
dodecyl sulfate, using apparatus 2 at 75 rpm for 60 minutes (PM= tablets obtained 
from physical mixtures, G = tablets obtained from granules). 
 
 
Spironolactone tablet formulations obtained from 
physical mixtures (PM1, PM2, PM5 and PM6), 
both with and without the excipient croscarmellose 
sodium, presented similar behavior. On the other 
hand, the dissolution profiles of spironolactone 
formulations PM3 and PM4 versus PM7 and PM8, 
were different, as they exhibited a faster rate of 
drug release (as observed for PM7 and PM8 over 
the first 30 minutes) than can be explained by the 
use of 1.0% croscarmellose sodium alone. For all 
of these formulations, the release of spironolactone 
improved according to the amount of surfactant 
added, but drug release for the tablets obtained 
from physical mixtures was never greater than 
65.0% within 90 minutes. 
For spironolactone, the fluid bed process created 
granules which were made into tablets with 
significantly better dissolution profiles (more than 
80.0% of the drug was dissolved) than the 
dissolution performance of the tablets obtained 
from physical mixtures, notwithstanding the 
presence of sodium dodecyl sulfate. 
Upon analyzing the formulations containing fluid 
bed material processed (G1 versus G5, G2 versus 
G6, G3 versus G7 and G4 versus G8) for 
nimodipine and spironolactone (Fig. 1 and 2), the 
dissolution profiles were observed to be very 
similar, but they had faster and higher drug release 
rates than tablets obtained from physical mixtures 
(PM1 to PM 8). Within 15 minutes, at least 60% 
of all of them had dissolved, notwithstanding the 
use of croscarmellose sodium or sodium dodecyl 
sulfate. 
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Figure 2 - Spironolactone dissolution profiles in 0.1 M hydrochloride acid with 0.1% sodium 
dodecyl sulfate, using apparatus 1 at 100 rpm for 90 minutes (PM= tablets obtained 
from physical mixtures, G = tablets obtained from granules). 
 
 
It is not easy to obtain fast and high rates of drug 
release from tablets when they contain drugs with 
poor water-solubility, like nimodipine and 
spironolactone, as can be observed in the 
dissolution profiles of the tablets obtained from the 
physical mixtures (Figures 1 and 2). However, 
granulation in the fluid bed equipment, by 
spraying the dispersed drug, was capable of 
generating granules that, in a solid dosage form, 
presented a dissolution profile with more than 
80.0% drug release within 20 minutes for 
nimodipine, and this was not related to the use of 
the disintegrant or the surfactant.  
The dissolution efficiency (DE) was calculated for 
all formulations, and the results are presented in 
Table 2. 
The analysis of variance of the DE values shows 
that the dissolution profiles are not similar for the 
formulations. The results of ANOVA are 
presented in Table 3 (nimodipine) and Table 4 
(spironolactone), and the interaction plots in 
Figures 3 and 4. 
The ANOVA results show that the amount of 
sodium dodecyl sulfate added for nimodipine, and 
the addition of croscarmellose sodium for 
spironolactone, did not significantly influence the 
DE values. However, a significant difference in 
dissolution efficiency for both drugs was related to 
the type of material processed (physical mixture or 
fluid bed granules), according to Tables 3 and 4. 
Considering that the use of disintegrants, such as 
croscarmellose sodium, in pharmaceutical 
formulations is a good strategy to facilitate the 
breaking down of tablets into smaller parts, thus 
allowing for faster drug release, it was thought that 
their addition would enhance the dissolution 
behavior of both drugs. However, only the 
physical mixtures were observed to be 
significantly affected by croscarmellose sodium. 
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Table 2 - Dissolution efficiencies (DE) of nimodipine and spironolactone formulations (PM = tablets obtained from 
physical mixtures; G = tablets obtained from fluid bed granules). 
Dissolution efficiency (%) 
Formulation Nimodipine Spironolactone PM G PM G 
1 5.6 73.0 11.6 95.3 
2 9.3 81.0 17.0 94.8 
3 29.2 66.3 20.8 84.3 
4 37.3 88.5 53.1 84.5 
5 9.1 76.6 59.4 95.4 
6 16.9 76.1 64.8 94.9 
7 45.7 68.0 72.8 87.2 
8 52.4 91.9 79.3 84.2 
 
Table 3 - ANOVA (analysis of variance) for DE results of nimodipine. 
Source DF SS MS F p-value 
Material 1 7302.1 7302.1 23.77 0.001 
Surfactant 3 242.5 80.8 0.26 0.850 
Disintegrant 1 1952.5 1952.5 6.36 0.030 
Error 10 3071.9 307.2   
Total 15 12569.0    
DF = degrees of freedom, SS = sum of square, MS = mean square. 
 
Table 4 - ANOVA (analysis of variance) for DE results of spironolactone. 
Source DF SS MS F p-value 
Material 1 10809.8 10809.8 95.07 0.000 
Surfactant 3 1590.0 1590.0 4.66 0.028 
Disintegrant 1 134.9 134.9 1.19 0.302 
Error 10 1137.0 1137.0   
Total 15 13671.7    
DF = degrees of freedom, SS = sum of square, MS = mean square. 
 
 
The interaction plot graphs enable the analysis of 
two variables at a time for nimodipine (Fig. 3) and 
spironolactone (Fig. 4). Considering the addition 
of croscarmellose sodium and the type of material 
(Figures 3 and 4), it was observed that the DE 
values for tablets obtained from physical mixtures 
of nimodipine and spironolactone without 
croscarmellose sodium (5.6, 9.3, 29.2 and 37.3%, 
for nimodipine and 11.6, 17.0, 20.8 and 53.1%, for 
spironolactone) were improved after the addition 
of croscarmellose sodium (9.1, 16.9, 45.7 and 
52.4% for nimodipine and 59.4, 64.8, 72.8 and 
79.3% for spironolactone). 
However the formulations obtained by granulation 
in the fluid bed equipment, after spraying the 
dispersed drug onto the powders, consistently 
showed better DE values, notwithstanding the use 
of croscarmellose sodium: the DE percentages in 
nimodipine tablets obtained from granules were 
73.0, 81.0, 66.3 and 88.5%, and after the addition 
of croscarmellose sodium, they rose to 76.6, 76.1, 
68.0 and 91.9% (Fig. 3). Similarly for 
spironolactone, the DE values obtained were 95.3, 
94.8, 84.3, 84.5%, and 95.4, 94.9, 87.2, 84.2% 
with croscarmellose sodium (Fig. 4). 
When the correlation between the amount of 
sodium dodecyl sulfate and the type of material is 
considered (Figures 3 and 4), the DE values of 
tablets obtained from physical mixtures for both 
nimodipine and spironolactone were observed to 
present increasing values according to the amount 
of surfactant added (0, 0.5, 1.0 or 2.0%). The use 
of surfactants is a formulation approach to enhance 
the dissolution properties of drugs with poor 
water-solubility, but their use is limited due to 
toxicity and side effects (Stegemann et al. 2007). 
For the tablets obtained from granules obtained by 
spraying the dispersed drug in the fluid bed 
equipment, the influence of sodium dodecyl 
sulfate disappears and all DE values are higher 
than the DE values for the tablets obtained from 
physical mixtures. 
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Figure 3 - Interaction plot (data means) for DE: nimodipine tablets obtained from physical 
mixtures (PM) and from granules (G). DE% = dissolution efficiency (y axis); 
concentrations of 0 to 2.0%, 0 and 1%, are from sodium dodecyl sulfate and sodium 
croscarmellose, respectively (x axis).   
 
 
 
 
Figure 4 - Interaction plot (data means) for DE: spironolactone tablets obtained from physical 
mixtures (PM) and from granules (G). DE% = dissolution efficiency (y axis); 
concentrations of 0 to 2.0%, 0 and 1%, are from sodium dodecyl sulfate and sodium 
croscarmellose, respectively (x axis).   
 
 
The interaction plot of the surfactant and the 
disintegrant (Figures 3 and 4) shows that DE 
values for the tablets containing nimodipine, 
obtained from both physical mixtures and 
granules, are affected by the use of croscarmellose 
sodium. Regarding spironolactone, the DE values 
are affected by the amount of sodium dodecyl 
sulfate used. However, the resulting improvement 
of those excipients is no greater than the 
improvement obtained using the fluid bed 
granulation process. It is probable that fluid bed 
granulation, with the drug dispersed onto powder, 
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leads to smaller and more uniform granules with 
better solubility properties in poorly water-soluble 
drugs, like nimodipine and spironolactone. 
The addition of dispersed drugs is an interesting 
resource in fluid bed technology, because this 
procedure avoids the loss of drugs that may 
otherwise adhere to the walls of the processing 
equipment, especially in the upper sections, near 
the filters. By blowing the active agents directly 
onto the surface of the particles inside the bed, and 
in the presence of flocculant, granules are formed 
and these do not easily adhere to the walls of the 
equipment.  
It is important to establish alternatives to enhance 
the dissolution rate of drugs with limited water 
solubility, notwithstanding the use of excipients, 
which can be toxic to humans. Fluid bed 
granulation has proved to be a process where the 
dissolution properties of water-insoluble drugs can 
be improved, without resorting to surfactants or 
disintegrants. 
This study proves that fluid bed granulation can 
improve the dissolution rate of nimodipine and 
spironolactone tablets, without the use of other 
formulation strategies to enhance dissolution 
properties. The use of sodium dodecyl sulfate was 
more important to spironolactone, and 
croscarmellose sodium was able to improve the 
dissolution profile of nimodipine tablets. However, 
the impact of the use of the fluid bed was the most 
representative factor in both cases. 
 
 
REFERENCES 
 
Ansari MA, Stepanek F. The evolution of 
microstructure in three-component granulation and its 
effect on dissolution. Part Sci Technol. 2008; 26: 55 
– 66. 
Bouffard J, Kaster M, Dumont H. Influence of process 
variable and physicochemical properties on the 
granulation mechanism of mannitol in a fluid bed top 
spray granulator. Drug Dev Ind Pharm. 2005; 31, 923 
– 933. 
British Pharmacopoeia, Her Majesty’s Stationery 
Office, London, 2010, 2941 – 2942. 
 
 
 
 
 
Fahmy RH, Kassem MA. Enhancement of famotidine 
dissolution rate through liquisolid tablets formulation: 
in vitro and in vivo evaluation. Eur J Pharm 
Biopharm. 2008; 69, 993 – 1003. 
Iveson SM, Litster JD, Hapgood K, Ennis BJ. 
Nucleation, growth and breakage phenomena in 
agitated wet granulation process: a review. Powder 
Technol. 2001; 117, 3 – 39. 
Leuner C, Dressman JB. Improving drug solubility for 
oral delivery using solid dispersions. Eur J Pharm 
Biopharm. 2000; 50, 47 – 60. 
Lindenberg M, Kopp S, Dressman JB. Classification of 
orally administered drugs on the World Health 
Organization model list of Essential Medicines 
according to the biopharmaceutics classification 
system. Eur J Pharm Biopharm. 2004; 58, 265 – 278. 
Murali Mohan Babu GV, Prasad ChDS, Ramana 
Murthy KV. Evaluation of modified gum karaya as 
carrier for the dissolution enhancement of poorly 
water soluble drug nimodipine. Int J Pharm. 2002; 
234, 1 – 17.  
Papageorgiou GZ, Bikiaris D, Karavas E, Politis S, 
Docoslis A, Park Y, et al. Effect of physical state and 
particle size distribution on dissolution enhancement 
of nimodipine/PEG solid dispersions prepared by 
metl mixing and solvente evaporation. The AAPS J. 
2006; 8, E623 – E631. 
Stegemann S, Leveiller F, Franchi D, de Jong H, 
Lindén H. When poor solubility becames an issue: 
from early stage to proof of concept. Eur J Pharm 
Sci. 2007; 31, 249 – 261. 
Tardos GI, Khan MI, Mort PR. Critical parameters and 
limiting conditions in binder granulation of fine 
powders. Powder Technol. 1997; 94, 245 – 258. 
United States Pharmacopeia (2009), 32 ed., United 
States Pharmacopeial Convention, Rockville MD, 
3293 – 3594. 
Vervaet C, Remon JP. Continuous granulation in 
pharmaceutical industry. Chem Eng Sci. 2005; 60, 
3949 – 3957. 
Vogt M, Kunath K, Dressman JB. Dissolution 
enhancement of fenofibrate by micronization, 
cogrinding and spray-drying: comparison with 
commercial preparations. Eur J Pharm Biopharm. 
2008a; 68, 283 – 288. 
Vogt M, Kunath K, Dressman JB. Dissolution 
improvement of four poorly water soluble drugs by 
cogrinding with commonly used excipients. Eur J 
Pharm Biopharm. 2008b; 68, 330 – 337. 
 
 
Received: March 22, 2010; 
Revised: November 10, 2010; 
Accepted: January 09, 2012 
 
 
 
 
